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The development of a specific agar diffusion bioassay for the quantitative determination of fluconazole 
formulated in capsules was carried out using a strain of Candida albicans ATCC 18804 as the test 
organism. A prospective validation of the method showed adequate linearity (r2=0.9995), precision 
(R.S.D. = 4.0% for intra-day and 4.5% for inter-day precision) and accuracy (mean recovery = 102.9%). 
High performance liquid chromatography was chosen as a comparison method for the fluconazole 
determination. The contents of fluconazole determined by both methods, for four capsule samples, showed 
a strong correlation, confirmed by Pearson’s correlation coefficient value (r = 0.9884). The bioassay is 
a suitable method for both research and pharmaceutical industry laboratories.
Uniterms: Fluconazole/quantitative determination. Microbiological assay/agar diffusion. High 
performance liquid chromatography.
Este trabalho visou ao desenvolvimento e validação de um método microbiológico por difusão em ágar para 
quantificação de fluconazol em cápsulas utilizando o isolado Candida albicans ATCC 18804 como reagente 
biológico. O método foi validado e foi verificada linearidade (r2=0,9995), precisão (D.P.R. = 4.0% para precisão 
intra-dia e 4,5% para precisão inter-dia) e exatidão (recuperação média = 102,9%). Concomitantemente, foi 
realizado o doseamento de fluconazol nas cápsulas por meio de cromatografia líquida de alta eficiência. Os 
teores encontrados por ambos os métodos demonstraram alta correlação, confirmada pelo Coeficiente de 
Correlação de Pearson (r = 0,9884). O ensaio microbiológico desenvolvido pode ser considerado ferramenta 
valiosa tanto para a pesquisa científica quanto para a rotina da indústria farmacêutica.
Unitermos: Fluconazol/quantificação. Ensaio microbiológico/por difusão em ágar. Cromatografia líquida 
de alta eficiência.
INTRODUCTION
Fluconazole, a triazole agent, is one of the most 
commonly prescribed systemic antifungals (Koks et 
al., 1996; Marchetti et al., 2001; Kim et al., 2007). It is 
well absorbed after oral administration and shows good 
penetration into cerebrospinal fluid (Harris et al., 1999). 
This agent is used in the treatment of oropharyngeal, 
esophageal, or vulvovaginal candidiasis, as well as other 
serious systemic candida infections. It is also used for 
the treatment of meningitis caused by Cryptococcus sp. 
(Mathy et al., 2003; Porta et al., 2005). Fluconazole is 
available commercially for oral administration in capsu-
les of 50, 150 and 200 mg. A sodium chloride solution of 
this agent for intravenous administration is also available 
(Porta et al., 2005).
The use of this drug is widespread around the world, 
as the pharmaceutical industry and even compounding 
pharmacies produce the capsules for human usage. It is 
important to mention that capsules with dosage lower than 
that recommended are ineffective and compromise patient 
health. Studies focused on fluconazole determination in 
pharmaceutical formulation by bioassay are scarce, where 
the majority of papers are related to its study in clinical 
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samples using a HPLC method (blood, serum, saliva 
or skin) (Harris et al., 1989; Rex et al., 1991; Garcia-
Hermoso et al., 1995; Koks et al., 1996; Hülsewede and 
Dermoumi, 1996; Cohen et al., 1997; Moraes et al., 1999; 
Abdel-Moety et al., 2002; Mathy et al., 2003; Marchetti 
et al., 2003; Porta et al., 2005; Kim et al., 2007; Lima et 
al., 2009).
The most commonly described assay for fluco-
nazole content in capsules are high performance liquid 
chromatography (HPLC), gas liquid chromatography and 
spectrophotometry (Harris et al., 1989; Rex et al., 1991; 
Moraes et al., 1999; Porta et al., 2005; Kim et al., 2007). 
These methods require expensive equipment and consi-
derable technician time (Rex et al., 1991). Furthermore, 
fluconazole, as with other antibiotics, may be also quan-
tified by bioassay for its activity assessment (Puranjoti et 
al., 1999; Porta et al., 2005), but experimental conditions 
such as concentrations of the inocula, incubation tempe-
rature and test microorganism are not yet well established 
official methods.
Previous studies focusing on fluconazole bioassay 
development presented methods used for determination of 
the antifungal levels in plasma, serum (Rex et al., 1991; 
Porta et al., 2005) and saliva (Koks et al., 1996). Studies 
of fluconazole determination in pharmaceutical capsules 
have used mainly HPLC and UV (Abdel-Moety et al., 
2002; Porta et al., 2005; Kim et al., 2007), while micro-
biological method use is scarce. This assay can reveal 
subtle changes not demonstrable by chemical methods. 
Moreover, it gives the possibility to evaluate the potency of 
fluconazole, which is considered important for the analysis 
of antibiotics (Salgado et al., 2006).
The purpose of this study was to develop and vali-
date a microbiological method to determine the potency 
of fluconazole in commercial capsules. The bioassay 
results were compared to those obtained by HPLC, using 
the same samples. 
MATERIAL AND METHODS
Reagents and materials
Fluconazole reference standard was kindly supplied 
by Pfizer. Fluconazole capsules (150 mg) were obtained 
from four different compounding pharmacies of Gover-
nador Valadares, Minas Gerais State, Brazil. Distilled 
water purified in a Millipore (Bedford, MA, USA) system 
was used in the analysis. Acetonitrile (HPLC grade) was 
purchased from Tedia (Fairfield, OH, USA) and dimethyl 
sulfoxide (DMSO) (analytical grade) from Synth (Diade-
ma, São Paulo State, Brazil).
Bioassay of fluconazole
A stock standard solution of 1000 mg/mL was pre-
pared by placing 10 mg of fluconazole reference standard 
into a flask and diluting in DMSO to a total volume of 
10 mL. This solution was further diluted in sterile distil-
led water to a concentration of 625.00 mg/mL, which was 
used for serial two-fold dilution up to 39.06 mg/mL. The 
standard tested concentrations were 625.00 (S
1
), 312.50 
(S
2
), 156.25 (R: reference concentration), 78.13 (S
4
) and 
39.06 (S
5
) mg/ml.
A pool of each sample of fluconazole capsules was 
made and a stock solution of 1000 mg/mL in DMSO was 
prepared. This solution was diluted in sterile distilled 
water to a concentration of 156.25 mg/mL (identical to the 
standard reference concentration - R). All the fluconazole 
solutions (standard and test) were prepared immediately 
before performing the test.
Candida albicans ATCC 18804 was maintained on 
Sabouraud dextrose slant agar at 4 °C. Prior to use, the mi-
croorganism was transferred to Sabouraud dextrose slant 
agar and incubated for 24 h at 28 °C. After this period, a 
small portion of the yeast was transferred to a sterile sali-
ne solution (0.9%) and the transmittance was adjusted to 
85% at a wavelength of 520 nm, which measured 1-5 x 
106 CFU/mL (Figueiredo et al., 2007). Further dilution of 
the inocula suspension was made in 15 mL of Sabouraud 
dextrose agar melted at 45 °C to achieve a final concen-
tration of 1-5 x 105 CFU/mL. 
Sterile Petri dishes (100 mm x 20 mm) were used in 
all microbiological tests. A base layer of Sabouraud dextrose 
agar (8 ml) was plated before the test to facilitate the visua-
lization of inhibition zones. After base layer solidification, 
the next layer, to be used for inoculation, was poured into 
Petri dishes on top of the base layer. The agar was allowed 
to gel at room temperature for 10 to 15 min. After solidifi-
cation, 5 mm-diameter wells were bored at six points for a 
5 x 1 assay (Figure 1). Five Petri dishes were used for each 
assay in order to test the reference concentration (R) conco-
mitantly with each standard or sample concentrations. Forty 
microliters of each standard or test solution were pipetted 
into individual wells. The plates were incubated at 28 °C 
for 24 h. The inhibition zone was measured using calipers. 
Assay plates were tested in triplicate (corresponding to 
15 dishes in each assay), resulting in nine measures of the 
standards S
1
, S
2
, S
4
 and S
5
 and the test sample. The R con-
centration was tested forty-five times (Figure 1) in order to 
fit data obtained in all the dishes.
The optimization of the previously mentioned expe-
rimental conditions were achieved by testing: (i) incuba-
tion time of 24 h and 36 h; (ii) incubation temperature of 
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28 °C and 37 °C and (iii) inocula concentration varying 
from 1-5 x 103 to 1-5 x 105 CFU/mL.
Correction of the inhibition zone (IZc) with the 
reference (R) concentration
The average of all measures of R concentration (in 
all the dishes) was used to fit the values of inhibition zones 
in each individual dish.
To fit the obtained data, the following equation was 
applied:
IZ
c
 = IZ + (R
A
 -R
s
)
where: IZ
c
 is the value of the corrected inhibition 
zone; IZ, the average value of the inhibition zone of the 
standard or tested sample in the studied dish; R
A
, the ave-
rage of the inhibition zone values for the R concentration 
in all dishes (a total of 45 values) and R
s
, the average of 
inhibition zone values for the R in the studied dish (a total 
of nine values) (Lima et al., 2009). 
The data analysis was made by plotting log
10
 of flu-
conazole concentration versus inhibition zones; the curve 
equation was obtained by regression analysis. Concen-
trations of test solutions were determined using the curve 
equation of the standard curve.
Method validation
The microbiological method was validated by evalu-
ation of linearity, precision and accuracy, according to the 
procedures described in ICH guidelines Q2 (R1).
(i) Linearity: in order to assess the linearity of the 
assay, five concentrations of the reference standard were 
tested (625.00; 312.50; 156.25; 78.16 and 39.06 µg/mL). A 
calibration curve for log
10
 of fluconazole concentration versus 
inhibition zones was plotted and the obtained data were sub-
jected to regression analysis using the Least Squares Method.
 (ii) Precision: the intra-day precision was evalu-
ated by analyzing six replicates of fluconazole solutions 
(n=6), at 100% of the test concentration (156.25 mg/mL). 
Similarly, the inter-day precision was evaluated on two 
consecutive days (n=12). The concentration of flucon-
azole in capsule samples was determined and the relative 
standard deviation (R.S.D.) was calculated.
 (iii) Accuracy: this was determined by adding known 
amounts of fluconazole reference standard (39.06, 117.18 
or 195.30 mg/mL) to a sample solution (39.06 mg/mL) 
at the beginning of the analyses, corresponding to 50, 100 
and 150% of the test concentration. At each level, solutions 
were prepared in triplicate and applied to the plate assay de-
scribed above. The recovery percentage of fluconazole was 
determined. In addition, the bioassay results were compared 
to a second known method (HPLC-UV).
HPLC assay for fluconazole
The HPLC analyses were carried out on a Agilent 
1200 system (Santa Clara, CA, USA), composed of a qua-
ternary pump, an auto sampler, a photodiode array detector 
(DAD) and HP ChemStation software. The chromatogra-
phic conditions employed were those described by Porta 
et al. (2005). The column used was a reversed-phase C
18
 
(150 × 4.6 mm I.D.; 5 µm particle size) from ACE (Aber-
deen, Scotland), at 30 °C. UV-photodiode array detection 
was performed at 260 nm. The mobile phase was com-
posed of acetonitrile and water (22:78), at a flow rate of 
1.0 mL/min. The injection volume was 20 µL.
Approximately 25 mg of fluconazole reference 
standard were accurately weighed in a volumetric flask 
of 50 ml and dissolved in mobile phase. The flask vo-
lume was adjusted to 50 ml with the same solvent. The 
sample solutions were prepared by weighing a portion 
of the capsule’s powder, equivalent to about 25 mg of 
fluconazole, and dissolving in mobile phase, obtaining a 
500 µg/mL solution. All solutions were filtered through 
0.45 µm membranes before injection. 
Analysis of fluconazole capsules
Four commercial samples of fluconazole capsules 
were analyzed using both the developed and validated mi-
FIGURE 1 - 5 x 1 assay: five Petri dishes were used. The reference concentration (R) was tested concomitantly with all other 
concentrations. S
1 
(625.00 µg/mL), S
2 
(312.50 µg/mL), R (156.25 µg/mL), S
4 
(78.16 µg/mL) and S
5 
(39.06 µg/mL) represent the 
standard solutions. T represents the sample solution (156.25 µg/mL).
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crobiological method and the HPLC method. The content 
results obtained by both methods were compared and the 
agreement between them was evaluated by the Pearson 
coefficient (r).
RESULTS AND DISCUSSION
Method development
In this study we developed and validated a bioassay 
to determine fluconazole potency in capsules. The stan-
dardization of experimental conditions is crucial to obtain 
reliable and reproducible results. In spite of achieving 
adequate results, the lack of this standardization is clearly 
detectable in previous studies involving potency determi-
nation of antifungals, since each paper describes a differ-
ent way of performing the tests. Firstly, the presence of a 
base layer without the inocula provided easier-to-measure 
inhibition zones. The described incubation temperatures 
were 30 °C (Espinel-Ingroff et al., 1977; Odds et al., 
1999), 32 °C (Purangioti et al., 1999), 35 °C (Pascual et 
al., 2007) and 37 °C (Law et al., 1994; Perea et al., 2000). 
The temperatures tested in the present paper (28 °C and 37 
°C) did not yield different results, revealing that both can 
be used in the experiments. Published incubation times 
varied from 14 h (Pascual et al., 2007) to 24 h (Odds et al., 
1999). The incubation time tested in our study (24 h) was 
adequate to provide sufficient yeast growth and regular 
inhibition zones. This was not observed when the plates 
were incubated for 36 h, which provided lower zones and 
culminated in significantly reduced concentrations (prob-
ably due to the more prominent yeast growth) which were 
not well correlated to the HPLC assay (data not shown).
A large number of strains have also been used as test 
organisms: Candida kefyr 706 (Garcia-Hermoso et al., 
1995), Candida kefyr ATCC46764 (Perea et al., 2000), 
Candida albicans DSY1024 (Marchetti et al., 2001), 
Candida albicans ATCC95020 (Pascual et al., 2007) and 
Sacharomyces cerevisiae ATCC2601 (Adams, 2006). The 
strain C. albicans ATCC 18804 used in this work was con-
sidered to be adequate for fluconazole testing. In addition, 
it would be very helpful if researchers and industries used 
the same strain to perform antifungal determination so as 
to improve test standardization. The inocula concentration 
of 1-5 x 105 CFU/mL provided the best visualization of 
the inhibition zones compared to the inocula with 103 and 
104 CFU/mL, for which zones were not clearly delineated. 
In our study design, we used six wells per plate (as 
depicted in Figure 1), which make possible lower devia-
tions due to the correction of the inhibition zone values 
by a standard concentration (R). Other researchers have 
used larger plates in which 16, 36 or even 38 wells were 
made (Rex et al., 1991; Perea et al., 2000; Marchetti et 
al., 2001; Pascual et al., 2007). However, a large number 
of wells on a single plate makes performing the assay and 
the measurements of the inhibition zones more difficult. 
Furthermore, the excessive manipulation of each plate 
increases the possibility of undesirable contamination.
Bioassay
The inhibition zones were clearly delineated by 
using optimized testing conditions. Triplicate wells gave 
the same zone diameters within 1 mm. The average of the 
corrected inhibition zones values for standard concentra-
tions were 16.61 mm (S
1
), 13.78 mm (S
2
), 10.72 mm (R), 
8.07 mm (S
4
) and 5.28 mm (S
5
). Calibration curves were 
plotted and the r2 value was > 0.9990. DMSO, at the final 
concentration, did not influence the C. albicans ATCC 
18804 growth.
Validation of bioassay
A good linear relationship (r2 = 0.9995) was found 
between the fluconazole concentrations and growth inhi-
bition zone diameter, in the assayed range. The regression 
analysis data are shown in Table I. The representative 
linear equation for fluconazole was 9.429x + 9.869. The 
low R.S.D. value (1.04%) indicated the precision of the 
calibration curve.
Precision was expressed as relative standard devia-
tion (R.S.D.). In the intra-day precision assay (n=6), the 
mean content of fluconazole was 95.8% (R.S.D. = 4.0%). 
For the inter-day precision (n=12), the obtained mean 
was 96.8% (R.S.D. = 4.5%). The obtained R.S.D. values 
confirmed the adequate precision of the method.
Accuracy was investigated by means of a standard 
addition experiment, at three concentration levels, in 
triplicate (n=9). The recovery percentages varied from 
101.5% to 104.4% (Table II). The mean recovery of 
TABLE I - Overview of the linearity data obtained for fluconazole
Parameters Regression analysis results
Regression coefficient 0.9995
Slope ± standard deviation 9.429 ± 0.118
Intercept ± standard deviation -9.869 ± 0.264
Relative standard deviation (%) 1.04
Concentration range (mg/ml) 39.06 - 625.00
Number of points 5
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102.9% assured accuracy of the method. In addition, an 
adequate correlation with HPLC-UV method was obtai-
ned, as depicted in Table III.
HPLC assay
Samples of four commercial fluconazole 150 mg 
capsules were quantified in triplicate by HPLC. The 
obtained chromatogram (Figure 2) shows a symmetrical 
peak, with a tailing factor of 1.09 and retention time of 
4.44 min. The fluconazole contents in each sample are 
presented in Table III. 
Correlation of bioassay results and HPLC
The correlation between both methods was evalua-
ted. Figure 3 demonstrates the high agreement regarding 
the zone inhibition of the bioassay and the peak area 
of the HPLC method, in five different concentrations 
(r = 0.9950). The contents of fluconazole determined by 
both methods, for four capsule samples, showed strong 
correlation, indicated by Pearson’s correlation coefficient 
value (r = 0.9884).
The data in Table III indicate higher contents of 
fluconazole determined by bioassay in comparison to the 
concentrations assayed by the HPLC method. This obser-
ved deviation may be due to the considerable differences 
between the two distinct methods, such as experimental 
conditions and detection techniques. In addition, bio-
assays can reveal subtle changes not demonstrable by 
chemical methods. However, the contents of fluconazole 
determined by both methods showed a strong correlation 
(r = 0.9884), which is clear evidence of the corresponden-
ce in the results. Similar results were found by Warnock 
(1988) when comparing bioassay and HPLC for determi-
nation of itraconazole.
The bioassay, as presented, is suitable for both rese-
arch and pharmaceutical industry laboratories. The major 
advantage of the bioassay is its low cost and relative simpli-
city; it is easy to perform and requires no special equipment 
(Rex et al., 1991; Perea et al., 2000). It is interesting to note 
that in some studies involving bioassay for fluconazole in 
FIGURE 2 - Chromatogram obtained with acetonitrile:water (22:78), using an ACE C18 column (250 × 4.6mm I.D.; 5 µm particle 
size), at 30 °C, detection at 260 nm. Retention time of fluconazole peak was 4.44 min.
TABLE II - Recovery of fluconazole in a standard addition 
experiment for accuracy evaluation
Sample
Added 
(mg/mL)
Found 
(mg/mL)* %
1 39.06 40.78 104.4
2 117.18 118.95 101.5
3 195.30 200.99 102.9
* average of three determinations
TABLE III - Fluconazole contents in capsule samples obtained 
by bioassay and HPLC methods
Samples
Fluconazole content (%)
Bioassay HPLC
1 103.9 99.1
2 95.6 90.7
3 95.5 90.7
4 103.2 100.3
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plasma and sera, the r2 values were lower than the value 
found in the present paper (Rex et al., 1991; Hüsewede, 
Dermoumi, 1996). In spite of this slight difference, our re-
sults showed bioassay to be reliable, which may encourage 
other authors and the pharmaceutical industry to perform 
it for fluconazole, concomitantly with the HPLC method. 
This is an important step for potency verification of antifun-
gals, even though this kind of test is not present in official 
pharmacopoeias (Farmacopéia Brasileira, 1988; British 
Pharmacopoeia, 2007; The United States Pharmacopoeia, 
2007). For antibacterial drugs, pharmacopoeias recommend 
the performing of both HPLC and bioassays, as the tests are 
complementary to each other.
Bioassays play an essential role in manufacturing 
and quality control of antibiotic medicines (Salgado et 
al., 2006). Therefore, the method reported here represents 
a simple and low cost assay to quantify fluconazole in 
capsules. The potential of adapting this method for use 
with other azole antifungals warrants further investigation.
In conclusion, the bioassay for the determination of 
fluconazole in capsules proved reliable when performed 
using an inoculum of 1-5 x 105 CFU/mL of C. albicans 
ATCC 18804 and an incubation time of 24h, at 28°C or 
37°C.
REFERENCES
ABDEL-MOETY, E. M.; KHATTAB, F. I.; KELANI, K. 
M.; ABOUAL-ALAMEIN, A. M. Chromatographic 
determination of clotrimazole, ketoconazole and fluconazole 
in pharmaceutical formulations. Farmaco, v.57, p.931-938, 
2002.
ADAMS, A. I. H.; STEPPE, M.; FRÖEHLICH, P. E.; 
BERGOLD, A. M. Comparison of microbiological and 
UV-spectrophotometric assays for determination of 
voriconazole in tablets. J. AOAC Int., v.89, p.960-965, 1996.
BRITISH Pharmacopoeia. London: Her Majesty’s Stationary 
Office, 2007. p.835-836
CLINICAL AND LABORATORY STANDARD INSTITUTE 
(CLSI). M27A2: Reference method for broth dilution 
antifungal susceptibility testing of yeasts. Approved 
standard. 2.ed. Wayne: Clinical and Laboratory Standards 
Institute, 2002. p.1-26.
CLINICAL AND LABORATORY STANDARDS INSTITUTE 
(CLSI). Reference method for broth dilution antifungal 
susceptibility testing of filamentous fungi. Wayne: Clinical 
and Laboratory Standards Institute, 2002. (Approved 
standard M38-A).
COHEN, L. G.; DIBIASO, A.; LISCO, S. J.; HURFORD, W. 
E. Fluconazole serum concentration and pharmacokinetics 
in an obese patient. Pharmacotherapy, v.17, p.1023-1026, 
1997.
ESPINEL-INGROF, A.; SHADOMY, S.; FISCHER, J. F. 
Bioassay for miconazole. Antimicrob. Agents Chemother., 
v.11, p.365-368, 1977.
FARMACOÉIA Brasileira. 4.ed. Atheneu: São Paulo, 1988. 
p.287.1-287.2. 
FIGUEIREDO, V. T.; SANTOS, D. A.; RESENDE, M. A.; 
HAMDAN, J. S. Identification and in vitro antifungal 
susceptibility testing of 200 clinical isolates of Candida 
spp. responsible for fingernail infections. Mycopathol., 
v.164, p.27-33, 2007.
GARCIA-HERMOSO, D.; DROMER, F.; IMPROVISIS, L.; 
PROVOST, F.; DUPONT, B. Fluconazole concentrations 
in saliva from AIDS patients with oropharyngeal candidosis 
refractory to treatment with fluconazole. Antimicrob. Agents 
Chemother., v.39, p.656-660, 1995.
HARRIS, S. C.; WALLACE, J. E.; FOULDS, G.; RINALDI, 
M. G. Assay of fluconazole by megabore capillary gas-
liquid chromatography with nitrogen-selective detection. 
Antimicrob. Agents Chemother., v.33, p.714-716, 1989.
HOSTETLER, J. S.; HEYKANTS, J.; CLEMONS, K. V.; 
WOESTENBORGHS, R.; HANSON, L. H.; STEVENS, 
D. A. Discrepancies in bioassay and chromatograph 
determinations explained by metabolism of itraconazole 
to hydroxyitraconazole: studies of interpatient variations 
in concentrations. Antimicrob. Agents Chemother., v.37, 
p.2224-2227, 1993.
FIGURE 3 - Correlation between HPLC and bioassay: The 
figure demonstrates the agreement between the responses of the 
two tested methods (r = 0.9950).
Comparison of microbiological assay and HPLC-UV 699
HÜLSEWEDE, J.  W.; DERMOUMI, H. Serum level 
determination of fluconazole by high-performance liquid 
chromatography and bioassay. Zentralbl. Bakteriol., v.283, 
p.492-496, 1996.
KEEVIL, B. G.; NEWMAN, S.; LOCKHART, S.; HOWARD, 
S. J.; MOORE, C. B.; DENNING, D. W. Validation of 
an assay for voriconazole in serum samples using liquid 
chromatograph-tandem mass spectrometry. Ther. Drug 
Monit., v.26, p.650-657, 1994.
KIM, S. S.; IM, H. T.; KANG, I. M.; LEE, H. S.; LEE, H. 
W.; CHO, S. H.; KIM, J. B.; LEE, K. T. An optimized 
analytical method of fluconazole in human plasma by 
high-performance liquid chromatography with ultraviolet 
detection and its application to a bioequivalence study. J. 
Chromatogr. B., v.852, p.174-179, 2007.
KOKS, C. H.; MEENHORST, P. L.; HILLEBRAND, M. J.; 
BULT, A.; BEIJNEN, J. H. Pharmacokinetics of fluconazole 
in saliva and plasma after administration of an oral 
suspension and capsules. Antimicrob. Agents Chemother., 
v.40, p.1935-1937, 1996.
LAW, D.; MOORE, C. B.; DENNING, D. W. Bioassay for 
serum itraconazole concentrations usin hydroxyitraconazole 
standards. Antimicrob. Agents Chemother., v.38, p.1561-
1566, 1994.
LIMA, P. M. A.; PRADO, N. D.; SILVA, M. L. M.; DINIZ, R. 
D. L.; QUEIROZ, K. M.; CÉSAR, I. C.; PIANETTI, G. A.; 
SANTOS, D. A. Determination of ketoconazole in capsules 
by HPLC and microbiological assay. J. AOAC Internat., 
v.92, p.1076-1081, 2009.
MARCHETTI, O.; MAJCHERCZYK, P. A.; GLAUSER, M. P.; 
BILLE, G.; MOREILLON, P.; SANGLARD, D. Sensitive 
bioassay for determination of fluconazole concentrations in 
plasma using a Candida albicans mutant hypersusceptible 
to azoles. Antimicrob. Agents Chemother., v.45, p.696-700, 
2001.
MATHY, F. X.; VROMAN, B.; NTIVUNWA, D.; WINNE, A. J. 
D.; VERBEECK, R. K.; PRÉAT, V. On-line determination 
of fluconazole in blood an dermal rat microdialysates by 
microbore high-performance liquid chromatograph. J. 
Chromat. B., v.787, p.323-331, 2003.
MORAES, L.A.; LERNER, F.E.; MORAES, M.E.; MORAES, 
M.O. ;  CORSO,  G. ;  DE NUCCI G.  Fluconazole 
bioequivalence study: quantification by tandem mass 
spectrometry. Ther. Drug Monit., v.21, p.200-207, 1999.
ODDS, F. C.; DUPONT, B.; RINALDI, M. G.; STEVENS, 
D. A.; WARNOCK, D. W.; WOESTENBORGHS, R. 
Bioassays for itraconazole blood levels: an interlaboratory 
collaborative study. J. Antimicrob. Chemother., v.43, p.723-
727, 1999.
PASCUAL, A.; NIETH, V.; CALANDRA, T.; BILLE, 
J.; BOLAY, S.; DECOSTERD, L. A.; BUCLIN, T.; 
MAJCHERCAYK, P. A.; SANGLARD, D.; MARCHETTI, 
O. Variability of voriconazole plasma levels measured by 
new high-performance liquid chromatograph and bioassay 
methods. Antimicrob. Agents Chemother., v.51, p.137- 143, 
2007.
PEREA, S.; PENNICK, G. J.; MODAK, A.; FOTHERGILL, A. 
W.; SUTTON, D. A.; SHEEHAN, D. J.; RINALDI, M. G., 
Comparison of high-performance liquid chromatographic 
and microbiological methods for determination of 
voriconazole levels in plasma. Antimicrob. Agents 
Chemother., v.44, p.1209-1213, 2000.
PORTA V.; CHANG, K. H.; STORPIRTIS, S. Evaluation 
of the bioequivalence of capsules containing 150 mg of 
fluconazole. Int. J. Pharm., v.288, p.81-86, 2005.
PURANJOTI, P.; KASINA, R.; TENJARLA, S. Microbiological 
and HPLC analysis of miconazole in skin, serum and phase-
solubility studies. J. Clin. Pharm. Therap., v.24, p.445-450, 
1999.
REX, J. H.; HANSON, L. H.; AMANTEA, M. A.; STEVENS, 
D. A.; BENNETT, J. E. Standardization of a fluconazole 
bioassay and correlation of results with those obtained by 
high-pressure liquid chromatography. Antimicrob. Agents 
Chemother., v.35, p.846-850, 1991.
SALGADO, H. R. N.; LOPES, C. C. G. O.; LUCCHESI, M. B. 
B. Microbiological assay for gatifloxacin in pharmaceutical 
formulations. J. Pharm. Biomed. Anal., v.40, p.443-446, 
2006.
UNITED States Pharmacopoeia. 30.ed. Rockville: United States 
Pharmacopeial Convention, 2007. p.2137-2139
K.M. Queiroz, Ma.L.M. Silva, N.D. Prado, P.M.A. Lima, R.D.L. Diniz, I.C. César, G.A. Pianetti, D.A. Santos.700
VALIDATION OF ANALYTICAL PROCEDURES: TEXT 
AND METHODOLOGY Q2 (R1) – ICH Harmonized 
Tripartite Guideline. International Conference on 
Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use, 2005. p. 1-13.
WARNOCK, D. W.; TURNER, A.; BURKE, J. Comparison of 
high performance liquid chromatograph and microbiological 
methods for determination of itraconazole. J. Antimicrob. 
Chemother., v.21, p.93-100, 1988.
Received for publication on 24th July 2008.
Accepted for publication on 29th January 2009.
